Sangamo Therapeutics (SGMO) Equity Average (2016 - 2025)
Historic Equity Average for Sangamo Therapeutics (SGMO) over the last 15 years, with Q3 2025 value amounting to $12.9 million.
- Sangamo Therapeutics' Equity Average fell 5886.13% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 5886.13%. This contributed to the annual value of $52.8 million for FY2024, which is 7203.69% down from last year.
- Sangamo Therapeutics' Equity Average amounted to $12.9 million in Q3 2025, which was down 5886.13% from $12.3 million recorded in Q2 2025.
- Sangamo Therapeutics' Equity Average's 5-year high stood at $483.4 million during Q1 2021, with a 5-year trough of $12.3 million in Q2 2025.
- Its 5-year average for Equity Average is $218.9 million, with a median of $284.6 million in 2023.
- Per our database at Business Quant, Sangamo Therapeutics' Equity Average soared by 1688.07% in 2021 and then crashed by 8587.85% in 2024.
- Quarter analysis of 5 years shows Sangamo Therapeutics' Equity Average stood at $390.7 million in 2021, then decreased by 22.68% to $302.1 million in 2022, then plummeted by 63.95% to $108.9 million in 2023, then plummeted by 71.58% to $31.0 million in 2024, then crashed by 58.25% to $12.9 million in 2025.
- Its Equity Average was $12.9 million in Q3 2025, compared to $12.3 million in Q2 2025 and $13.8 million in Q1 2025.